★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Zoetis Inc. (ZTS) Moat Analysis
Zoetis Inc.
ZTS · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Zoetis Inc. is a Delaware animal-health company with one direct NYSE listing and no ADR mapping in this record. At July 31, 2026, exactly 413,223,602 common shares were outstanding, down from 414,154,046 at June 30. Q2 revenue was $2,468M: Companion Animal supplied 69.2%, Livestock 29.6%, and Contract Manufacturing & Human Health 1.2%. Companion Animal retains a strong brand-trust moat plus moderate field-service and time-limited IP advantages, but U.S. revenue fell amid price sensitivity, generic entry, and competitive pressure, contradicting current pricing power. Livestock has moderate regulated-process know-how, field support, and brand trust; its former strong capacity score confused manufacturing complexity with scarce proprietary capacity. Livestock showed selective price contribution across international cattle, poultry, and fish, while consolidated producer bargaining remains a counterweight.
Primary segment
Companion Animal Products
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 6 tags
Updated 2026-08-23
Segments
Companion Animal Products
Companion animal veterinary medicines, vaccines and diagnostics
Revenue
69.2%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Livestock Products
Livestock animal health medicines and vaccines (cattle, swine, poultry, aquaculture)
Revenue
29.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Client Supply Services & Human Health
Contract manufacturing services (animal health) and limited human health products
Revenue
1.2%
Structure
Competitive
Pricing
weak
Share
—
Peers
—
Moat Claims
Companion Animal Products
Companion animal veterinary medicines, vaccines and diagnostics
Revenue share uses Q2 2026 Companion Animal revenue of $1,708M divided by total revenue of $2,468M. Product-species operating profit is not disclosed because Zoetis reports profit through U.S. and International geographic segments.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Quality, safety, and veterinarian familiarity can sustain branded-product loyalty even after patent or regulatory exclusivity ends. The score remains strong rather than exceptional because Q2 showed substantial U.S. competitive, generic, and affordability pressure in key franchises.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Adverse-event publicity or label changes harming trust
- Channel shift toward powerful retailers and e-commerce
Leading indicators
- Price/mix contribution in companion animal revenue
- Veterinarian recommendation rates for key franchises
- Adverse-event reports / regulatory communications
Counterarguments
- Clinically similar alternatives can win on price or availability
- Large rivals can outspend on marketing and medical education
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
A 4,150-person sales organization with veterinary and technical specialists supports clinic education and product adoption. It is costly for small entrants to reproduce, but other global animal-health incumbents provide comparable coverage and consolidated clinic groups can centralize purchasing.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Clinic consolidation reduces value of rep relationships
- Competitors matching field coverage and specialist resources
- Digital channels partially substituting in-person support
Leading indicators
- Field headcount and veterinary specialist retention
- Sales per rep and coverage metrics
- Clinic group penetration (enterprise accounts won/lost)
Counterarguments
- Other global incumbents also run large field organizations
- Large corporate clinic groups may centralize purchasing and limit rep influence
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents/trademarks and (where applicable) regulatory data exclusivity protect differentiated products, but expirations invite aggressive generic competition.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expirations / loss of exclusivity
- At-risk generic launches and patent challenges
- Pricing pressure via discounts/rebates vs generics
Leading indicators
- Products nearing loss of exclusivity (% of sales)
- Generic approval/launch activity in key markets
- Litigation outcomes and settlement terms
Counterarguments
- Generic entrants can rapidly erode share once protection ends
- Some therapies are substitutable across brands, limiting IP-based pricing power
Livestock Products
Livestock animal health medicines and vaccines (cattle, swine, poultry, aquaculture)
Revenue share uses Q2 2026 Livestock revenue of $731M divided by total revenue of $2,468M. Revenue rose 12.3% year over year, with U.S. cattle demand helped by screwworm response and international growth spanning demand, geographic expansion, and selective price.
Learning Curve Yield
Supply
Learning Curve Yield
Strength
Durability
Confidence
Evidence
Complex, regulated manufacturing and the validation required to change production sites support moderate process know-how and qualification barriers. The former strong capacity score was not supported: large rivals also operate qualified plants, 140 third-party CMOs reduce exclusivity, and sole sourcing is partly a disruption risk.
Learning Curve Yield moat: definition, examples, and stocks
Erosion risks
- Manufacturing disruptions, quality deviations or key site outages
- Supply chain shocks impacting biological inputs
- Competitors expanding capacity in priority categories
Leading indicators
- Stock-out frequency in vaccines/biologics
- Batch rejection rates / quality metrics
- Capex levels and capacity expansion announcements
Counterarguments
- Large competitors also have global manufacturing footprints
- Reliance on third-party CMOs can reduce differentiation if competitors access the same CMOs
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Veterinary and technical specialists support herd and flock protocols and key-account adoption. The advantage is moderate because large integrated producers exert purchasing leverage and global competitors can bundle similar technical service.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Producer consolidation reduces the number of decision-makers
- Competitors offering comparable technical service
- Remote/digital advisory reducing differentiation
Leading indicators
- Account wins/losses among large producers and integrators
- Veterinary specialist retention and coverage
- Protocol adherence and repeat purchasing by large accounts
Counterarguments
- Integrated producers may prioritize price over service
- Competitors can bundle services with products in tenders
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Proven efficacy and safety in production settings sustains repeat purchasing, but price sensitivity is higher than in companion animal markets.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Producer focus on cost per dose and tendering
- Generic competition in mature categories
- Public policy/consumer pressure altering product mix
Leading indicators
- Gross margin trend in livestock portfolio
- Share of sales exposed to tenders/large accounts
- Regulatory restrictions affecting product classes
Counterarguments
- Many livestock categories are closer to commodity competition
- Bundling by competitors can outweigh brand preference
Client Supply Services & Human Health
Contract manufacturing services (animal health) and limited human health products
Revenue share uses Q2 2026 Contract Manufacturing & Human Health revenue of $29M divided by total revenue of $2,468M, adjusted by one unit in the sixth decimal so the three product-group shares sum exactly to 1. Long-term unsatisfied performance obligations were not material.
Evidence
Quality and safety concerns... contribute to brand loyalty... brand loyalty continues even after loss of patent-based and regulatory exclusivity.
Direct support for brand-driven demand retention (pricing resilience + lower churn).
As of December 31, 2025, our sales organization consisted of approximately 4,150 employees.
Scale of field organization supports dense coverage and relationship advantages.
Our sales organization also includes technical and veterinary operations specialists... providing scientific consulting support.
Specialist support raises switching costs for practices and helps defend product protocols.
Our product portfolio enjoys the protection of more than 5,500 granted patents and 1,600 pending patent applications.
Shows large IP portfolio supporting exclusivity and differentiation.
We face competition from lower-priced generic alternatives to many of our products that no longer have patent protection.
Direct acknowledgment that IP protection is time-limited and contested.
Showing 5 of 10 sources.
Risks & Indicators
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Adverse-event publicity or label changes harming trust
- Channel shift toward powerful retailers and e-commerce
- Clinic consolidation reduces value of rep relationships
- Competitors matching field coverage and specialist resources
- Digital channels partially substituting in-person support
Leading indicators
- Price/mix contribution in companion animal revenue
- Veterinarian recommendation rates for key franchises
- Adverse-event reports / regulatory communications
- Share of sales from products approaching loss of exclusivity
- Field headcount and veterinary specialist retention
- Sales per rep and coverage metrics
Research ZTS elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.